

26 June 2023

Dear colleague

It is with a mix of pride and regret that we write to inform you that, after 22 remarkable years, the NCRI will be winding down.

NCRI was established to formalise connections between organisations funding research into cancer, in order to identify where cancer research was most needed.

Since then the cancer research landscape has matured significantly and we are proud that many of the original purposes of the NCRI have been achieved or taken over as business as usual by Partners.

However, uncertainty in the wider economic and research environment has had an impact.

NCRI consulted widely with stakeholders last year to produce a strategy fit for the future. This identified a compelling set of priorities, but has raised significant questions around the sustainability of NCRI's operating and funding model, which we have not been able to resolve in such a way which would deliver long term viability for the organisation.

Reluctantly therefore, the Board decided that the risk of operational failure was too great to continue.

This decision has not been taken lightly and has huge impact on the NCRI staff. We are grateful for their continued support, hard work and professionalism at such a challenging time.

The Board is now working on the required steps to wind down the charity, identifying and securing our assets; financial, data and IP. The Trustees have an obligation to apply these assets in a manner which is consistent with NCRI's research charitable purposes, and as part of this exercise we will be consulting with Partners and other stakeholders, who might take forward some of NCRI's activities.

The NCRI Board is extremely grateful for your contribution to the national cancer research agenda through your collaboration with the NCRI.

Yours sincerely

Fiona Driscoll, NCRI Chair On behalf of the NCRI Board of Trustees

National Cancer Research Institute, 2 Redman Place, London, E20 1JQ T: +44 (0)20 3469 8798 W: www.ncri.org.uk